Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elagolix in Endometriosis-Associated Pain
NCT05648669Phase 3Unknown
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2022
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in endometriosis comparing Elagolix with Elagolix placebo (2 arms). Primary endpoints: Percentage of Responders of Dysmenorrhea (DYS) at 12 weeks and Percentage of Responders of Non-Menstrual Pelvic Pain (NMPP) at 12 weeks. Status: unknown.
02
Drugs
elagolix
03
Conditions
endometriosis
Beyond the preview
Go deeper on NCT05648669.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05648669.